ReviewPulmonary circulation2016
Pulmonary hypertension in patients with heart failure and preserved ejection fraction: differential diagnosis and management.
Review in Pulmonary circulation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 27 citations in OpenAlex.
- Genetic variation in RYR1 is associated with heart failure progression and mortality in a diverse patient population.Frontiers in cardiovascular medicine · 2025Article
- Development of a wearable belt with integrated sensors for measuring multiple physiological parameters related to heart failure.Scientific reports · 2022Article
- Relevance of comorbidities on initial combination therapy in pulmonary arterial hypertension.ERJ open research · 2022Article
- Medical Therapy for Heart Failure with Preserved Ejection Fraction.Methodist DeBakey cardiovascular journal · 2022Review
- Pulmonary hypertension due to left heart disease with pulmonary arterial wedge pressure ≤15 mm Hg.Herz · 2021Article
- Heart failure with preserved ejection fraction based on aging and comorbidities.Journal of translational medicine · 2021Review
- The Heart Failure with Preserved Ejection Fraction Conundrum-Redefining the Problem and Finding Common Ground?Current heart failure reports · 2020Review
- EXPRESS: Statement on imaging and pulmonary hypertension from the Pulmonary Vascular Research Institute (PVRI).Pulmonary circulation · 2019Article
- Identifying At-Risk Patients with Combined Pre- and Postcapillary Pulmonary Hypertension Using Interventricular Septal Angle at Cardiac MRI.Radiology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The most common cause of pulmonary hypertension (PH) due to left heart disease (LHD) was previously rheumatic mitral valve disease. However, with the disappearance of rheumatic fever and an aging population, nonvalvular LHD is now the most common cause of group 2 PH in the developed world. In this review, we examine the challenge of investigating patients who have PH and heart failure with preserved ejection fraction (HF-pEF), where differentiating between pulmonary arterial hypertension (PAH) and PH-LHD can be difficult, and also discuss the entity of combined precapillary and postcapillary PH. Given the proven efficacy of targeted therapy for the treatment of PAH, there is increasing interest in whether these treatments may benefit selected patients with PH associated with HF-pEF, and we review current trial data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.